DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Thursday, May 15, 2014, at 4:00 p.m. EDT to discuss the Company’s financial and operating performance for its quarter ended March 31, 2014, and the status of the Company’s product development and marketing activities.
Corgenix invites all those interested in hearing management’s discussion of the quarter results to join the call by dialing:
U.S. attendees: (800) 862-9098
International attendees: +1 785 424
1051
Conference code is: CORGENIX
A question-and-answer session will follow the presentation by Corgenix management.
A replay will be available for 30 days following the call by dialing (800) 753-0348 for U.S. participants and +1 402 220 2672 for international participants.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases (including the world’s only non-blood-based test for aspirin effect), bone and joint disorders and a line of unique detection products for viral hemorrhagic disease. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website).